Please note – you will leave a website owned by MacroGenics, Inc.
MacroGenics is not responsible for any content on the third party website.
Overview
MacroGenics has a diverse portfolio of oncology product candidates with several clinical trials currently underway or planned for the near future. Set forth below is the company’s development pipeline of product candidates for which we have retained commercialization or other important rights in the U.S. or more broadly (as of Feb. 24, 2022).
In addition to the molecules identified below, MacroGenics has out-licensed various other clinical-stage product candidates for which it retains certain economic rights. These include retifanlimab and teplizumab.
| Program (Target) | Potential Indication(s) | First-in-Human (Phase 1) | Proof-of-Concept (Phase 2) |
Pivotal (Phase 3) |
Major Market Rights | ||
|---|---|---|---|---|---|---|---|
| MGC018 (B7-H3) |
mCRPC, NSCLC, SCCHN, Melanoma |
placeholder
|
 |
||||
| Multiple Solid Tumors (+lorigerlimab) |
placeholder
|
||||||
| Enoblituzumab (B7-H3) |
SCCHN (Head & Neck Cancer) (+retifanlimab/tebotelimab) |
placeholder
|
|
Greater China  |
|||
| Lorigerlimab (PD-1 × CTLA-4) |
MSS CRC, NSCLC, mCRPC, Melanoma |
placeholder
|
|
||||
| Tebotelimab (PD-1 × LAG-3) |
Solid Tumors & Heme Malignancies |
placeholder
|
|
Greater China |
|||
| IMGC936 (ADAM9) |
NSCLC, Gastric, Pancreatic, TNBC and Other Solid Tumors |
placeholder
|
50/50  |
||||
| MGD024 (CD123 × CD3) |
CD123+ Heme Malignancies |
placeholder
Plan to initiate in 2022a
|
|
||||
Oncology
MGC018 (B7-H3)
mCRPC, NSCLC, SCCHN, Melanoma
| Phase 1 | Phase 2 | Phase3 |
|---|---|---|
|
placeholder
|
||
Multiple Solid Tumors (+lorigerlimab)
| Phase 1 | Phase 2 | Phase3 |
|---|---|---|
|
placeholder
|
||
Major Market Rights:
Enoblituzumab (B7-H3)
SCCHN (Head & Neck Cancer) (+retifanlimab/tebotelimab)
| Phase 1 | Phase 2 | Phase3 |
|---|---|---|
|
placeholder
|
||
Major Market Rights:
Greater China
Lorigerlimab
(PD-1 × CTLA-4)
(PD-1 × CTLA-4)
MSS CRC, NSCLC, mCRPC, Melanoma
| Phase 1 | Phase 2 | Phase3 |
|---|---|---|
|
placeholder
|
||
Major Market Rights:
Tebotelimab
(PD-1 × LAG-3)
(PD-1 × LAG-3)
Solid Tumors & Heme Malignancies
| Phase 1 | Phase 2 | Phase3 |
|---|---|---|
|
placeholder
|
||
Major Market Rights:
Greater China
IMGC936
(ADAM9)
(ADAM9)
NSCLC, Gastric, Pancreatic, TNBC and Other Solid Tumors
| Phase 1 | Phase 2 | Phase3 |
|---|---|---|
|
placeholder
|
||
Major Market Rights:
50/50
MGD024
(CD123 × CD3)
(CD123 × CD3)
CD123+ Heme Malignancies
| Phase 1 | Phase 2 | Phase3 |
|---|---|---|
|
placeholder
Plan to initiate in 2022a |
||
Major Market Rights:
MGD = DART MGA = AntibodyMGC = ADC